Table 2.
Associations between genus-specific HPV seroreactivity and BCC cases and controls
| Control (n=300) |
BCC (n=224) |
BCC (n=141) |
||
|---|---|---|---|---|
| n (%) | n (%) | OR (95% CI)1 | OR (95% CI)2 | |
|
| ||||
| Alpha | ||||
|
| ||||
| Seronegative | 194 (64.7) | 121 (54.0) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 106 (35.3) | 103 (46.0) | 1.61 (1.11–2.35) | 1.68 (1.09–2.59) |
|
| ||||
| 1 type | 59 (19.7) | 52 (23.2) | 1.50 (0.94–2.38) | 1.55 (0.91–2.65) |
|
| ||||
| ≥ 2 types | 92 (30.7) | 80 (35.7) | 1.59 (1.03–2.45) | 1.38 (0.84–2.29) |
|
| ||||
| ptrend=0.01 | ptrend=0.02 | |||
|
| ||||
| Beta | ||||
|
| ||||
| Seronegative | 119 (39.7) | 72 (32.1) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 181 (60.3) | 152 (67.9) | 1.32 (0.90–1.93) | 1.07 (0.69–1.66) |
|
| ||||
| 1 type | 47 (15.7) | 42 (18.8) | 1.35 (0.79–2.32) | 0.93 (0.70–1.73) |
|
| ||||
| 2-3 types | 51 (17.0) | 40 (17.8) | 1.30 (0.76–2.21) | 1.30 (0.70–2.42) |
|
| ||||
| 4-8 types | 36 (12.0) | 36 (15.2) | 1.75 (0.97–3.15) | 1.01 (0.51–2.01) |
|
| ||||
| > 8 types | 47 (15.7) | 36 (16.1) | 1.02 (0.59–1.78) | 1.08 (0.57–2.02) |
|
| ||||
| ptrend=0.43 | ptrend=0.72 | |||
|
| ||||
| Gamma | ||||
|
| ||||
| Seronegative | 145 (48.3) | 73 (32.6) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 155 (51.7) | 151 (67.4) | 1.78 (1.22–2.60)3 | 1.58 (1.02–2.44) |
|
| ||||
| 1 type | 63 (21.0) | 71 (31.7) | 2.06 (1.29–3.27)3 | 1.86 (1.09–3.17) |
|
| ||||
| ≥2 types | 47 (15.7) | 51 (22.8) | 1.75 (1.08–2.85) | 1.84 (1.04–3.24) |
|
| ||||
| ptrend=0.03 | ptrend=0.17 | |||
|
| ||||
| Mu | ||||
|
| ||||
| Seronegative | 204 (68.0) | 138 (61.6) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 96 (32.0) | 86 (38.4) | 1.56 (1.06–2.30) | 1.38 (0.89–2.13) |
|
| ||||
| Nu | ||||
|
| ||||
| Seronegative | 266 (88.7) | 198 (88.4) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 34 (11.3) | 26 (11.6) | 1.00 (0.56–1.77) | 1.25 (0.64–2.42) |
|
| ||||
| Control antigens | ||||
|
| ||||
| JCV | ||||
|
| ||||
| Seronegative | 108 (36.0) | 62 (27.7) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 192 (64.0) | 162 (72.3) | 1.32 (0.89–1.96) | 1.34 (0.84–2.11) |
|
| ||||
| KIV | ||||
|
| ||||
| Seronegative | 24 (8.0) | 14 (6.3) | 1.00 (Reference) | 1.00 (Reference) |
|
| ||||
| Seropositive | 276 (92.0) | 210 (93.8) | 0.88 (0.42–1.83) | 0.81 (0.35–1.88) |
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV, human papillomavirus; JCV, JC virus; KIV, KI virus; OR, odds ratio.
1
OR and 95% CI adjusted for age and sex.
2
OR and 95% CI adjusted for age and sex, restricted to participants aged 40–69 years. The age-restricted analysis included 141 BCC cases and 243 controls.
3
Statistical significance retained after correction for multiple comparisons (β-coefficient P<0.01).